FindTrial
Sign In

Anakinra Prefilled Syringe

DRUG4 trials

Sponsors

Adel Helmy, University Hospital, Basel, Switzerland, Karolinska University Hospital, Hellenic Institute for the Study of Sepsis

Conditions

Community-acquired PneumoniaCovid-19Diabetes Mellitus Type 2 in ObeseGlucose Metabolism Disorders (Including Diabetes Mellitus)Hospital-acquired PneumoniaInflammationMetabolic DiseaseTraumatic Brain INjury

Phase 2

IL-1ra Dose-range Study for Moderate-to-severe TBI Patients
NCT02997371
Adel HelmyTraumatic Brain INjury
Start: 2017-10-31End: 2021-10-31Target: 60Updated: 2017-05-08
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes
TerminatedNCT04227769
University Hospital, Basel, SwitzerlandDiabetes Mellitus Type 2 in Obese, Glucose Metabolism Disorders (Including Diabetes Mellitus), Inflammation +1
Start: 2020-01-13End: 2024-05-28Updated: 2025-01-29
A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study
NCT04412291
Karolinska University HospitalCovid-19
Start: 2020-06-11End: 2021-06-30Target: 120Updated: 2021-02-18
Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia
CompletedNCT05785442
Hellenic Institute for the Study of SepsisCommunity-acquired Pneumonia, Hospital-acquired Pneumonia
Start: 2023-03-06End: 2024-06-28Updated: 2024-07-31

Related Papers

Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial.
2025-12-29
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial
PLoS ONE2023-12-298 citations